XML 50 R35.htm IDEA: XBRL DOCUMENT v3.24.2
Investments Accounted for Using the Equity Method (Tables)
 6 Months Ended
Jun. 30, 2024
Interests In Other Entities [Abstract]  
Summary of Investments in Associates and Joint Ventures
Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2023), and comprise:
(€ million)% interestJune 30, 2024December 31, 2023
EUROAPI (a)
29.8 72 162 
Infraserv GmbH & Co. Höchst KG (b)
31.2 89 90 
MSP Vaccine Company (c)
50.0 90 96 
Other investments— 64 76 
Total

315424
(a)The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€2.55 as of June 30, 2024, and €5.73 as of December 31, 2023).
(b)Joint venture.
(c)Joint venture MSP Vaccine Company owns 100% of MCM Vaccine BV.
Summary of Principal Transactions and Balances with Related Parties
The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:
(€ million)June 30, 2024June 30, 2023December 31, 2023
Sales
59 64157
Royalties and other income
61 3263
Accounts receivable and other receivables
278 213249
Purchases of goods and services
345 302642
Accounts payable and other payables63 9771